Microvascular Plasticity and Experimental Heart Failure

Bernard I. Lévy

Angiogenesis is an essential process in adulthood during wound healing and restoration of blood flow to injured tissues. Angiogenesis is regulated by a very sensitive interplay of growth factors and inhibitors; their imbalance can lead to very diverse diseases. Excessive angiogenesis is involved in malignant, diabetic retinopathy and inflammatory disorders (eg, rheumatoid arthritis, psoriasis, atherosclerosis). Conversely, insufficient angiogenesis may underlie conditions such as ischemic heart diseases, stroke, hypertension, and diabetes. Hence, during the evolution of these degenerative pathologies, inadequate blood vessel growth and insufficient microvascular density leads to poor circulation and tissue suffering or, ultimately, necrosis and death.1

In several physiological conditions, such as muscular exercise training and detraining, acclimatization to altitude, and aging, an adaptation of the microvascular network structure and function to new conditions has been reported.2,3 Interestingly, there is a close link between cerebral angiogenesis and learning; during cognitive decline in relation to senescence or degenerative cerebral diseases, microvascular density is decreased in specific cerebral areas. Specifically, there is a striking relationship between the capillary density, the cerebral tissue blood flow, the local glucose use, and other measures of neuronal signaling, such as the Na+/K+ ATPase (reviewed in Reference 4). Therefore, microvascular plasticity, defined as the ability of the arteriole and capillary network to adapt to the metabolic local conditions by proangiogenesis or antiangiogenesis processes, likely plays a key role in many tissue homeostatic processes.

Microvasculature and Arterial Hypertension

In hypertension, the role of microcirculation (arteriolar and capillary) is of particular importance in increasing peripheral resistance by decreasing the number of vessels per unit of tissue volume; a phenomenon known as “microvascular rarefaction.” Ruedemann,5 in 1933, was the first to describe microvascular rarefaction in the conjunctiva of the rat with Goldblatt hypertension. Experimental evidence suggests that microcirculatory rarefaction, which manifests as an increased intercapillary distance, is responsible for nonuniform tissue perfusion leading to hypoperfused and hypoxia- or dilated cardiomyopathy. In a recent work, by using quantitative histological measurements, Karcha et al8 evidenced that the mean diffusion distance increased from left
ventricular myocardium from control to dilated cardiomyopathy and ischemic and inflammatory cardiomyopathies. Therefore, insufficient supply of oxygen to myocardial tissue may lead to chronic hypoxia and myocytes dysfunction.

In the present issue of Hypertension, Izumiya et al. report a fascinating experimental study: they showed that administration of a vascular endothelial growth factor (VEGF) trap reagent, able to block signaling of all VEGF isoforms, to mice subjected to pressure overload by surgical aortic constriction resulted in diminished cardiac hypertrophy and promoted the progression to heart failure. The same group had described previously in conditional transgenic mice by the sequential development of adaptive cardiac hypertrophy with preserved contractility in the acute phase and dilated cardiomyopathy in the chronic phase after the induction of an activated Akt1 gene in the heart. In this setting, coronary angiogenesis was enhanced during the acute phase of adaptive cardiac growth but reduced as hearts underwent pathological remodeling.

In the present study, the authors provided evidence that inactivation of endogenous VEGF impaired adaptive cardiac hypertrophy in response to pressure overload and contributed to the rapid progression from compensatory cardiac hypertrophy to heart failure. This underlines the importance of microvascular plasticity to allow adaptation of the vascular network and, thus, the oxygen supply, to increased metabolic demand related to the pressure overload. Adapted microvascular plasticity allows compensatory cardiac hypertrophy. In the absence of such vascular plasticity because of VEGF blockade, myocardium hypertrophy is unable to develop, thereby contributing to the switch toward cardiac failure, that is, to cardiomyocytes in vivo ultimately becoming maladaptive (Figure).

In the present study, the authors provided evidence that inactivation of endogenous VEGF impaired adaptive cardiac hypertrophy in response to pressure overload and contributed to the rapid progression from compensatory cardiac hypertrophy to heart failure. This underlines the importance of microvascular plasticity to allow adaptation of the vascular network and, thus, the oxygen supply, to increased metabolic demand related to the pressure overload. Adapted microvascular plasticity allows compensatory cardiac hypertrophy. In the absence of such vascular plasticity because of VEGF blockade, myocardium hypertrophy is unable to develop, thereby contributing to the switch toward cardiac failure, that is, to cardiomyocytes in vivo ultimately becoming maladaptive (Figure).

This important work raises at least 3 series of pathophysiological and clinical questions. First, is it possible and beneficial to stimulate expression of angiogenic growth factors in hypertensive cardiopathy to delay the occurrence of heart failure? If yes, how can this be achieved? Are conventional pharmacological treatments able to increase VEGF expression in the myocardium? Second, is it possible, by restoring the production of VEGF, to stabilize heart failure and even to reverse it? Third, antiangiogenic agents, such as bevacizumab, have been rationally designed to target VEGF in patients with metastatic colorectal cancer to block tumor angiogenesis. The side effect profile of bevacizumab has been evaluated and makes it a suitable adjunct to standard chemotherapy; it is now approved for use in the United States, the European Union, and other markets worldwide. However, the most commonly observed adverse events is hypertension, which is generally mild to moderate and manageable. Is hypertension related to capillary rarefaction in patients receiving anti-VEGF treatments? Could antiangiogenic therapy favor a mismatch between adaptive cardiac hypertrophy and coronary capillary density? Would it accelerate the switch from cardiac hypertrophy to heart failure in treated patients? Would these phenomena be reversible after cessation of the antiangiogenic treatment?

The present study by Izumiya et al strongly suggests that defects and impairments in the main proangiogenic factors are likely involved in the occurrence of heart failure in a model of pressure overload–induced cardiac hypertrophy. If these findings are confirmed in a clinical setting, VEGF and its receptors could be a new molecular target for treating severe heart failure.

Acknowledgments
This work has been supported by Inserm and Société pour le Développement de la Recherche Cardiovasculaire.

References
3. Dunn JF, Grinberg O, Roche M, Nwaigwe CI, Hou HG, Swartz HM. Noninvasive assessment of cerebral oxygenation during accl-


Microvascular Plasticity and Experimental Heart Failure
Bernard I. Lévy

_Hypertension_. 2006;47:827-829; originally published online March 27, 2006;
doi: 10.1161/01.HYP.0000215283.53943.39
_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/47/5/827

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Hypertension_ is online at:
http://hyper.ahajournals.org/subscriptions/